ArticleJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2008
VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines.
Article in Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Interferons in vitreoretinal diseases; a review on their clinical application, and mechanism of action.International ophthalmology · 2024Pooled it
- A pilot study of bevacizumab and interferon-α2b in ocular melanoma.American journal of clinical oncology · 2011Trial
- A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.Journal of immunotherapy (Hagerstown, Md. : 1997)Trial
- Interferon as a novel agent for management of macular edema: Where do we stand?Indian journal of ophthalmology · 2026Review
- "Cytokine-Mediated tumor sensitization: mechanistic frameworks and therapeutic opportunities in cancer Immunotherapy".Clinical and experimental medicine · 2026Review
- Sex-specific angiogenic responses in endothelial cells-role of the pluripotency factor OCT4.Angiogenesis · 2025Article
- Article
- The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.Targeted oncology · 2021Review
- A digital mRNA expression signature to classify challenging Spitzoid melanocytic neoplasms.FEBS open bio · 2020Article
- Functional annotation of melanoma risk loci identifies novel susceptibility genes.Carcinogenesis · 2020Article
- Genetic perturbation of IFN-α transcriptional modulators in human endothelial cells uncovers pivotal regulators of angiogenesis.Computational and structural biotechnology journal · 2020Article
- Biomimetic Molecular Signaling using DNA Walkers on Microparticles.Scientific reports · 2017Article
- IFNα-mediated remodeling of endothelial cells in the bone marrow niche.Haematologica · 2017Article
- Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.Frontiers in immunology · 2015Review
- Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10.International journal of oncology · 2014Article
- Type I interferons: key players in normal skin and select cutaneous malignancies.Dermatology research and practice · 2014Review
- Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma.British journal of cancer · 2012Article
- The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Antiproliferative Properties of Type I and Type II Interferon.Pharmaceuticals (Basel, Switzerland) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Interferon-alpha (IFN-alpha) is employed in the treatment of malignant melanoma; however, it mediates regression of disease in only 10-15% of patients. Currently, its mechanism of action is uncharacterized. Low-dose IFN-alpha exerts anti-angiogenic effects when used in the treatment of life-threatening hemangiomas of infancy, suggesting anti-angiogenesis as a mechanism of action. IFN-alpha may exert its anti-tumor effect in the setting of advanced malignancy by inhibiting the secretion of vascular endothelial growth factor (VEGF), a pro-angiogenic substance. We hypothesized that IFN-alpha would decrease the release of VEGF by melanoma tumors. We studied the effect of IFN-alpha on VEGF production in nine human melanoma cell lines. We also examined VEGF levels in 49 patients with advanced malignancies who received low-dose IFN-alpha and interleukin-12 (IL-12) on an NCI-sponsored phase I trial. Human melanoma cell lines produced varying amounts of VEGF in vitro (60-1500 pg/mL at 48 h). Certain melanoma cell lines such as 18105 MEL secreted low levels of VEGF (152 pg/mL) after 48 h of culture, whereas other lines secreted very high levels (FO-1 3,802 pg/mL). Treatment of melanoma cells with IFN-alpha (2000 U/mL) decreased VEGF secretion by 40-60% in VEGF-high cell lines; however, this effect was not demonstrated in VEGF-low cell lines. In cancer patients, pretreatment VEGF plasma levels varied from 471 to 4200 pg/mL. A decrease in VEGF plasma levels after treatment directly correlated with the number of treatment cycles administered (Pearson correlation, p = 0.04). In summary, IFN-alpha inhibits VEGF secretion by melanoma cell lines in vitro and may have similar actions in malignancies that respond to IFN-alpha treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.